Loading...
A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
Joudi, Maryam Binabaj, Maryam Moradi Porouhan, Pejman PeyroShabany, Babak Fazilat-Panah, Danial Khajeh, Mahtab Mehrabian, Arezoo Dehghani, Mansoureh Welsh, James S.
Joudi, Maryam
Binabaj, Maryam Moradi
Porouhan, Pejman
PeyroShabany, Babak
Fazilat-Panah, Danial
Khajeh, Mahtab
Mehrabian, Arezoo
Dehghani, Mansoureh
Welsh, James S.
Citations
Altmetric:
Genre
Journal article
Date
2022-03-01
Advisor
Committee member
Department
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.3389/fendo.2022.798975
Abstract
Aim: To determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer. Methods: In this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 ± 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects. Results: The presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively. Discussion: The inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.
Description
Citation
Joudi M, Moradi Binabaj M, Porouhan P, PeyroShabany B, Tabasi M, Fazilat-Panah D, Khajeh M, Mehrabian A, Dehghani M, Welsh JS, Keykhosravi B, Akbari Yazdi A, Ariamanesh M, Ghasemi A, Ferns G and Javadinia SA (2022) A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome? Front. Endocrinol. 13:798975. doi: 10.3389/fendo.2022.798975
Citation to related work
Frontiers Media
Has part
Frontiers in Endocrinology, Vol. 13
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu